首页 > 最新文献

Clinical and Translational Gastroenterology最新文献

英文 中文
Metagenomics Analysis Reveals Unique Gut Microbiota Signature of Slow-Transit Constipation. 元基因组学分析揭示了缓慢型便秘的独特肠道微生物群特征。
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 DOI: 10.14309/ctg.0000000000000766
Kyungsun Han, Braden Kuo, Hamed Khalili, Kyle Staller

Introduction: Altered gut microbiota may play a role in slow-transit constipation (STC). We conducted a study of gut microbiota composition and functionality in STC using metagenomic analyses.

Methods: We assembled a clinical cohort of 24 patients with STC physiology age- and sex-matched to 24 controls. We performed shotgun metagenomic sequencing followed by prediction of metabolite composition from functional profiles.

Results: In a middle-aged (mean 55.3 years), predominantly female cohort, there were no significant differences in α-diversity indices, but permutational multivariate analysis of variance analysis showed significant between-group differences (R 2 = 0.050, P < 0.001) between STC patients and controls. Gordonibacter pamelaeae , Bifidobacterium longum , Firmicutes bacterium co-abundance gene group 94, and Anaerotruncus colihominis were more abundant in STC, whereas Coprococcus comes and Roseburia intestinalis were more abundant in controls. Gut-derived metabolites varying in STC relative to controls were related to bile acid and cholesterol metabolism.

Discussion: We found a unique metagenomic and metabolomic signature of STC.

简介:肠道微生物群的改变可能是导致慢传输性便秘(STC)的原因之一。我们利用元基因组分析法对慢行性便秘患者的肠道微生物群组成和功能进行了研究:方法:我们组建了一个临床队列,其中包括 24 名与 24 名对照组年龄和性别相匹配的 STC 生理病患者。我们进行了霰弹枪元基因组测序,然后根据功能图谱预测代谢物组成:结果:在以女性为主的中年(平均 55.3 岁)组群中,α 多样性指数无显著差异,但 permutational 多变量方差分析显示组间差异显著(R2=0.050,p 讨论:我们发现了 STC 独特的元基因组和代谢组特征。
{"title":"Metagenomics Analysis Reveals Unique Gut Microbiota Signature of Slow-Transit Constipation.","authors":"Kyungsun Han, Braden Kuo, Hamed Khalili, Kyle Staller","doi":"10.14309/ctg.0000000000000766","DOIUrl":"10.14309/ctg.0000000000000766","url":null,"abstract":"<p><strong>Introduction: </strong>Altered gut microbiota may play a role in slow-transit constipation (STC). We conducted a study of gut microbiota composition and functionality in STC using metagenomic analyses.</p><p><strong>Methods: </strong>We assembled a clinical cohort of 24 patients with STC physiology age- and sex-matched to 24 controls. We performed shotgun metagenomic sequencing followed by prediction of metabolite composition from functional profiles.</p><p><strong>Results: </strong>In a middle-aged (mean 55.3 years), predominantly female cohort, there were no significant differences in α-diversity indices, but permutational multivariate analysis of variance analysis showed significant between-group differences (R 2 = 0.050, P < 0.001) between STC patients and controls. Gordonibacter pamelaeae , Bifidobacterium longum , Firmicutes bacterium co-abundance gene group 94, and Anaerotruncus colihominis were more abundant in STC, whereas Coprococcus comes and Roseburia intestinalis were more abundant in controls. Gut-derived metabolites varying in STC relative to controls were related to bile acid and cholesterol metabolism.</p><p><strong>Discussion: </strong>We found a unique metagenomic and metabolomic signature of STC.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e1"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142119130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fecal and Serum Granulocyte Protein Levels in Inflammatory Bowel Disease and Irritable Bowel Syndrome and Their Relation to Disease Activity. 炎症性肠病和肠易激综合征的粪便和血清粒细胞蛋白水平及其与疾病活动的关系。
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 DOI: 10.14309/ctg.0000000000000733
Helena Ekoff, Niclas Rydell, Per M Hellström, Robert Movérare

Introduction: Neutrophilic calprotectin (CP) and myeloperoxidase (MPO), neutrophil gelatinase-associated lipocalin (NGAL), and eosinophil-derived neurotoxin (EDN) are suggested proxy markers for gut inflammation. However, there are insufficient supporting data for MPO, NGAL, and EDN.

Methods: In a cross-sectional investigation including adult patients, we studied the ability of CP, MPO, NGAL, and EDN, measured in fecal and serum samples, to differentiate between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), and to predict disease activity.

Results: Fifty-nine patients had ulcerative colitis (UC), 38 had Crohn's disease, and 100 patients had IBS. The protein concentrations were higher in patients with IBD in the fecal samples ( P < 0.001) and the serum samples ( P < 0.01), and they correlated weakly (r s ≤0.38) between the sample sources. Fecal EDN was higher in patients with Crohn's disease compared with UC (1.79 vs 0.50 mg/kg, P = 0.016). The neutrophilic proteins were superior to EDN in the fecal samples for differentiating between patients with IBD and IBS. Fecal MPO (cutoff: 0.86 mg/kg) had the highest sensitivity (74.7%) and specificity (84.6%). Combining fecal CP and MPO increased the sensitivity to 82.3% (specificity: 73.6%). NGAL (cutoff: 196.9 μg/L) showed the best discriminating performance in serum (sensitivity: 62.9%; specificity: 68.0%). Serum NGAL (cutoff: 272.4 μg/L) predicted active disease in UC (Partial Mayo Score ≥2) with a sensitivity and specificity of 57.1% and 83.3%, respectively.

Discussion: Fecal MPO and serum NGAL are promising novel biomarkers, in addition to fecal CP, for differentiating between IBD and IBS. Serum NGAL may also predict disease activity in patients with UC.

导言:中性粒细胞钙蛋白(CP)和髓过氧化物酶(MPO)、中性粒细胞明胶酶相关脂褐质(NGAL)和嗜酸性粒细胞衍生神经毒素(EDN)被认为是肠道炎症的替代标记物。然而,MPO、NGAL 和 EDN 的支持数据并不充分:在一项包括成年患者在内的横断面调查中,我们研究了粪便和血清样本中测得的 CP、MPO、NGAL 和 EDN 在区分炎症性肠病(IBD)和肠易激综合征(IBS)以及预测疾病活动性方面的能力:59名患者患有溃疡性结肠炎(UC),38名患者患有克罗恩病(CD),100名患者患有肠易激综合征。在粪便样本中,IBD 患者的蛋白质浓度更高(p 结论:粪便 MPO 和血清凝乳酶原的浓度在 IBD 患者中更高:除粪便 CP 外,粪便 MPO 和血清 NGAL 是很有前途的新型生物标记物,可用于区分 IBD 和 IBS。血清 NGAL 还能预测 UC 患者的疾病活动性。
{"title":"Fecal and Serum Granulocyte Protein Levels in Inflammatory Bowel Disease and Irritable Bowel Syndrome and Their Relation to Disease Activity.","authors":"Helena Ekoff, Niclas Rydell, Per M Hellström, Robert Movérare","doi":"10.14309/ctg.0000000000000733","DOIUrl":"10.14309/ctg.0000000000000733","url":null,"abstract":"<p><strong>Introduction: </strong>Neutrophilic calprotectin (CP) and myeloperoxidase (MPO), neutrophil gelatinase-associated lipocalin (NGAL), and eosinophil-derived neurotoxin (EDN) are suggested proxy markers for gut inflammation. However, there are insufficient supporting data for MPO, NGAL, and EDN.</p><p><strong>Methods: </strong>In a cross-sectional investigation including adult patients, we studied the ability of CP, MPO, NGAL, and EDN, measured in fecal and serum samples, to differentiate between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), and to predict disease activity.</p><p><strong>Results: </strong>Fifty-nine patients had ulcerative colitis (UC), 38 had Crohn's disease, and 100 patients had IBS. The protein concentrations were higher in patients with IBD in the fecal samples ( P < 0.001) and the serum samples ( P < 0.01), and they correlated weakly (r s ≤0.38) between the sample sources. Fecal EDN was higher in patients with Crohn's disease compared with UC (1.79 vs 0.50 mg/kg, P = 0.016). The neutrophilic proteins were superior to EDN in the fecal samples for differentiating between patients with IBD and IBS. Fecal MPO (cutoff: 0.86 mg/kg) had the highest sensitivity (74.7%) and specificity (84.6%). Combining fecal CP and MPO increased the sensitivity to 82.3% (specificity: 73.6%). NGAL (cutoff: 196.9 μg/L) showed the best discriminating performance in serum (sensitivity: 62.9%; specificity: 68.0%). Serum NGAL (cutoff: 272.4 μg/L) predicted active disease in UC (Partial Mayo Score ≥2) with a sensitivity and specificity of 57.1% and 83.3%, respectively.</p><p><strong>Discussion: </strong>Fecal MPO and serum NGAL are promising novel biomarkers, in addition to fecal CP, for differentiating between IBD and IBS. Serum NGAL may also predict disease activity in patients with UC.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e1"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141449858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the Efficacy Between the Dual Therapy of Tegoprazan and the Quadruple Therapy of Tegoprazan: A Randomized Controlled Multicenter Study. 特戈普拉赞双重疗法与特戈普拉赞四重疗法的疗效比较:一项随机对照多中心研究。
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-10-01 DOI: 10.14309/ctg.0000000000000699
Han-Ning Liu, Rui Wang, Yan Cao, Feng Xian, Xian-Jin Bi, Ding-Jian Wu, Bin Wang, Xing-Wei Wang, Chun-Hui Lan

Introduction: Tegoprazan (TPZ), a potassium-competitive acid blocker, exerts a strong acid-suppression effect and a rapid onset of action. However, research on TPZ-amoxicillin (TA) dual treatment is limited. Here, we compared the safety and efficacy of TPZ-amoxicillin dual treatment and TPZ, bismuth potassium citrate, amoxicillin, and clarithromycin (TBAC) quadruple therapy in patients newly diagnosed with H. pylori infection over a 14-day treatment period.

Methods: A total of 236 patients newly diagnosed with H. pylori were enrolled in this multicenter, prospective, open-label, and randomized controlled study. Patients randomly received either TA dual or TBAC quadruple therapy. The incidence of adverse reactions and treatment compliance were recorded and then analyzed.

Results: The intention-to-treat analysis revealed that H. pylori eradication rates were 83.9% (95% confidence interval 78.2%-91.3%) and 81.4% (95% confidence interval 74.2%-88.5%) for the TA and TBAC groups, respectively, with no statistically significant difference between them ( P = 0.606). The per-protocol analysis revealed that the H. pylori eradication rates were 88.3% and 84.8% for the TA and TBAC groups, respectively ( P = 0.447). The incidence of adverse reactions was significantly lower in the TA group than in the TBAC group (4.2% vs 15.3%, P = 0.004). Moreover, the TA group demonstrated substantially higher treatment compliance than the TBAC group (94.1% vs 89.0%, P = 0.020).

Discussion: The TA dual therapy successfully eradicated H. pylori with a high eradication rate and a low incidence of adverse reactions. Therefore, this treatment is recommended as an alternative course for patients newly diagnosed with H. pylori infection.

简介替戈普拉赞(Tegoprazan,TPZ)是一种钾竞争性酸阻滞剂,具有很强的抑酸作用,而且起效迅速。然而,有关 TPZ-阿莫西林(TA)双重治疗的研究还很有限。在此,我们比较了TPZ-阿莫西林双重治疗与TPZ、枸橼酸铋钾、阿莫西林和克拉霉素(TBAC)四联疗法在新诊断的幽门螺杆菌感染患者中14天治疗期的安全性和有效性:这项多中心、前瞻性、开放标签和随机对照研究共招募了 236 名新确诊的幽门螺杆菌感染患者。患者随机接受 TA 双联疗法或 TBAC 四联疗法。研究记录并分析了不良反应发生率和治疗依从性:意向治疗分析显示,TA组和TBAC组的幽门螺杆菌根除率分别为83.9%(95%置信区间[CI] 78.2%-91.3%)和81.4%(95%置信区间[CI] 74.2%-88.5%),差异无统计学意义(P = 0.606)。按协议分析显示,TA组和TBAC组的幽门螺杆菌根除率分别为88.3%和84.8%(P = 0.447)。TA组的不良反应发生率明显低于TBAC组(4.2% vs. 15.3%,P = 0.004)。此外,TA组的治疗依从性大大高于TBAC组(94.1% vs. 89.0%,P = 0.020):TA双重疗法成功根除了幽门螺杆菌,根除率高,不良反应发生率低。因此,建议将该疗法作为新诊断幽门螺杆菌感染患者的替代疗法。
{"title":"Comparison of the Efficacy Between the Dual Therapy of Tegoprazan and the Quadruple Therapy of Tegoprazan: A Randomized Controlled Multicenter Study.","authors":"Han-Ning Liu, Rui Wang, Yan Cao, Feng Xian, Xian-Jin Bi, Ding-Jian Wu, Bin Wang, Xing-Wei Wang, Chun-Hui Lan","doi":"10.14309/ctg.0000000000000699","DOIUrl":"10.14309/ctg.0000000000000699","url":null,"abstract":"<p><strong>Introduction: </strong>Tegoprazan (TPZ), a potassium-competitive acid blocker, exerts a strong acid-suppression effect and a rapid onset of action. However, research on TPZ-amoxicillin (TA) dual treatment is limited. Here, we compared the safety and efficacy of TPZ-amoxicillin dual treatment and TPZ, bismuth potassium citrate, amoxicillin, and clarithromycin (TBAC) quadruple therapy in patients newly diagnosed with H. pylori infection over a 14-day treatment period.</p><p><strong>Methods: </strong>A total of 236 patients newly diagnosed with H. pylori were enrolled in this multicenter, prospective, open-label, and randomized controlled study. Patients randomly received either TA dual or TBAC quadruple therapy. The incidence of adverse reactions and treatment compliance were recorded and then analyzed.</p><p><strong>Results: </strong>The intention-to-treat analysis revealed that H. pylori eradication rates were 83.9% (95% confidence interval 78.2%-91.3%) and 81.4% (95% confidence interval 74.2%-88.5%) for the TA and TBAC groups, respectively, with no statistically significant difference between them ( P = 0.606). The per-protocol analysis revealed that the H. pylori eradication rates were 88.3% and 84.8% for the TA and TBAC groups, respectively ( P = 0.447). The incidence of adverse reactions was significantly lower in the TA group than in the TBAC group (4.2% vs 15.3%, P = 0.004). Moreover, the TA group demonstrated substantially higher treatment compliance than the TBAC group (94.1% vs 89.0%, P = 0.020).</p><p><strong>Discussion: </strong>The TA dual therapy successfully eradicated H. pylori with a high eradication rate and a low incidence of adverse reactions. Therefore, this treatment is recommended as an alternative course for patients newly diagnosed with H. pylori infection.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e1"},"PeriodicalIF":3.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140334906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep Learning and Automatic Differentiation of Pancreatic Lesions in Endoscopic Ultrasound: A Transatlantic Study. 深度学习与内窥镜超声波胰腺病变的自动分辨--一项跨大西洋研究。
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-26 DOI: 10.14309/ctg.0000000000000771
Miguel Mascarenhas Saraiva, Mariano González-Haba, Jessica Widmer, Francisco Mendes, Tamas Gonda, Belen Agudo, Tiago Ribeiro, António Costa, Yousef Fazel, Marcos Eduardo Lera, Eduardo Horneaux de Moura, Matheus Ferreira de Carvalho, Alexandre Bestetti, João Afonso, Miguel Martins, Maria João Almeida, Filipe Vilas-Boas, Pedro Moutinho-Ribeiro, Susana Lopes, Joana Fernandes, João Ferreira, Guilherme Macedo

Introduction: Endoscopic ultrasound (EUS) allows for characterization and biopsy of pancreatic lesions. Pancreatic cystic neoplasms (PCN) include mucinous (M-PCN) and nonmucinous lesions (NM-PCN). Pancreatic ductal adenocarcinoma (P-DAC) is the commonest pancreatic solid lesion (PSL), followed by pancreatic neuroendocrine tumor (P-NET). Although EUS is preferred for pancreatic lesion evaluation, its diagnostic accuracy is suboptimal. This multicentric study aims to develop a convolutional neural network (CNN) for detecting and distinguishing PCN (namely M-PCN and NM-PCN) and PSL (particularly P-DAC and P-NET).

Methods: A CNN was developed with 378 EUS examinations from 4 international reference centers (Centro Hospitalar Universitário São João, Hospital Universitario Puerta de Hierro Majadahonda, New York University Hospitals, Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo). About 126.000 images were obtained-19.528 M-PCN, 8.175 NM-PCN, 64.286 P-DAC, 29.153 P-NET, and 4.858 normal pancreas images. A trinary CNN differentiated normal pancreas tissue from M-PCN and NM-PCN. A binary CNN distinguished P-DAC from P-NET. The total data set was divided into a training and testing data set (used for model's evaluation) in a 90/10% ratio. The model was evaluated through its sensitivity, specificity, positive and negative predictive values, and accuracy.

Results: The CNN had 99.1% accuracy for identifying normal pancreatic tissue, 99.0% and 99.8% for M-PCN and NM-PCN, respectively. P-DAC and P-NET were distinguished with 94.0% accuracy.

Discussion: Our group developed the first worldwide CNN capable of detecting and differentiating the commonest PCN and PSL in EUS images, using examinations from 4 centers in 2 continents, minimizing the impact of the demographic bias. Larger multicentric studies are needed for technology implementation.

内窥镜超声(EUS)可对胰腺病变进行定性和活检。胰腺囊性肿瘤(PCN)包括粘液性病变(M-PCN)和非粘液性病变(NM-PCN)。胰腺导管腺癌(P-DAC)是最常见的胰腺实体瘤(PSL),其次是胰腺神经内分泌肿瘤(P-NET)。虽然 EUS 是评估胰腺病变的首选方法,但其诊断准确性并不理想。这项多中心研究旨在开发一种卷积神经网络(CNN),用于检测和区分 PCN(即 M-PCN 和 NM-PCN)和 PSL(尤其是 P-DAC 和 P-NET)。利用 4 个国际参考中心(圣若昂大学中心医院、普埃尔塔德埃罗马亚达洪达大学医院、纽约大学医院、FMUSP Clínicas 医院)的 378 例 EUS 检查结果开发了 CNN。共获得 126.000 张图像--19.528 张 M-PCN、8.175 张 NM-PCN、64.286 张 P-DAC、29.153 张 P-NET 和 4.858 张正常胰腺图像。三元 CNN 将正常胰腺组织与 M-PCN 和 NM-PCN 区分开来。二元 CNN 将 P-DAC 与 P-NET 区分开来。整个数据集按 90/10% 的比例分为训练数据集和测试数据集(用于模型评估)。通过灵敏度、特异性、阳性和阴性预测值以及准确度对模型进行评估。CNN 识别正常胰腺组织的准确率为 99.1%,识别 M-PCN 和 NM-PCN 的准确率分别为 99.0% 和 99.8%。区分 P-DAC 和 P-NET 的准确率为 94.0%。我们的研究小组利用来自两大洲 4 个中心的检查结果,开发出了全球首个能够检测和区分 EUS 图像中最常见的 PCN 和 PSL 的 CNN,最大程度地减少了人口统计学偏差的影响。该技术的实施需要更大规模的多中心研究。
{"title":"Deep Learning and Automatic Differentiation of Pancreatic Lesions in Endoscopic Ultrasound: A Transatlantic Study.","authors":"Miguel Mascarenhas Saraiva, Mariano González-Haba, Jessica Widmer, Francisco Mendes, Tamas Gonda, Belen Agudo, Tiago Ribeiro, António Costa, Yousef Fazel, Marcos Eduardo Lera, Eduardo Horneaux de Moura, Matheus Ferreira de Carvalho, Alexandre Bestetti, João Afonso, Miguel Martins, Maria João Almeida, Filipe Vilas-Boas, Pedro Moutinho-Ribeiro, Susana Lopes, Joana Fernandes, João Ferreira, Guilherme Macedo","doi":"10.14309/ctg.0000000000000771","DOIUrl":"10.14309/ctg.0000000000000771","url":null,"abstract":"<p><strong>Introduction: </strong>Endoscopic ultrasound (EUS) allows for characterization and biopsy of pancreatic lesions. Pancreatic cystic neoplasms (PCN) include mucinous (M-PCN) and nonmucinous lesions (NM-PCN). Pancreatic ductal adenocarcinoma (P-DAC) is the commonest pancreatic solid lesion (PSL), followed by pancreatic neuroendocrine tumor (P-NET). Although EUS is preferred for pancreatic lesion evaluation, its diagnostic accuracy is suboptimal. This multicentric study aims to develop a convolutional neural network (CNN) for detecting and distinguishing PCN (namely M-PCN and NM-PCN) and PSL (particularly P-DAC and P-NET).</p><p><strong>Methods: </strong>A CNN was developed with 378 EUS examinations from 4 international reference centers (Centro Hospitalar Universitário São João, Hospital Universitario Puerta de Hierro Majadahonda, New York University Hospitals, Hospital das Clínicas Faculdade de Medicina da Universidade de São Paulo). About 126.000 images were obtained-19.528 M-PCN, 8.175 NM-PCN, 64.286 P-DAC, 29.153 P-NET, and 4.858 normal pancreas images. A trinary CNN differentiated normal pancreas tissue from M-PCN and NM-PCN. A binary CNN distinguished P-DAC from P-NET. The total data set was divided into a training and testing data set (used for model's evaluation) in a 90/10% ratio. The model was evaluated through its sensitivity, specificity, positive and negative predictive values, and accuracy.</p><p><strong>Results: </strong>The CNN had 99.1% accuracy for identifying normal pancreatic tissue, 99.0% and 99.8% for M-PCN and NM-PCN, respectively. P-DAC and P-NET were distinguished with 94.0% accuracy.</p><p><strong>Discussion: </strong>Our group developed the first worldwide CNN capable of detecting and differentiating the commonest PCN and PSL in EUS images, using examinations from 4 centers in 2 continents, minimizing the impact of the demographic bias. Larger multicentric studies are needed for technology implementation.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dynamics of Splenic Transient Elastography in Patients With Alcohol Use Disorder. 酒精使用障碍患者脾脏瞬态弹性成像的动态变化。
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-23 DOI: 10.14309/ctg.0000000000000770
Mian B Khalid, Hanna L Blaney, Anusha Vittal, Alexander H Yang, Bilal A Asif, Natasha Kamal, Elizabeth C Wright, Chris Koh, David George, David Goldman, Yvonne Horneffer, Nancy Diazgranados, Theo Heller

Introduction: Splenic stiffness (SS) measurement (SSM) is an evolving noninvasive assessment to evaluate portal hypertension. Studies with respect to SSM in patients with alcohol use disorder are limited.

Methods: We studied patients seeking treatment for alcohol use disorder in an inpatient treatment protocol at the National Institutes of Health and parsed SSM into 3 groups based on degree of change.

Results: The improved SS group had statistically higher initial SSM and a nonstatistically increased liver stiffness measurement compared with others.

Discussion: SS is dynamic in a subset of patients immediately after alcohol cessation, and improved SS is associated with a normalization of platelet count.

简介:脾脏僵硬度测量(SSM)是一种不断发展的评估门静脉高压的非侵入性评估方法。有关酒精使用障碍(AUD)患者脾脏硬度测量的研究非常有限:我们研究了在美国国立卫生研究院住院治疗方案中寻求治疗的 AUD 患者,并根据变化程度将 SSM 分成 3 组:结果:与其他组别相比,"改善 "SSM组的初始SSM在统计学上更高,肝脏硬度测量(LSM)在统计学上没有增加:讨论:部分患者在戒酒后会立即出现 SS 动态变化,SSM 的改善与血小板计数的正常化有关。
{"title":"Dynamics of Splenic Transient Elastography in Patients With Alcohol Use Disorder.","authors":"Mian B Khalid, Hanna L Blaney, Anusha Vittal, Alexander H Yang, Bilal A Asif, Natasha Kamal, Elizabeth C Wright, Chris Koh, David George, David Goldman, Yvonne Horneffer, Nancy Diazgranados, Theo Heller","doi":"10.14309/ctg.0000000000000770","DOIUrl":"10.14309/ctg.0000000000000770","url":null,"abstract":"<p><strong>Introduction: </strong>Splenic stiffness (SS) measurement (SSM) is an evolving noninvasive assessment to evaluate portal hypertension. Studies with respect to SSM in patients with alcohol use disorder are limited.</p><p><strong>Methods: </strong>We studied patients seeking treatment for alcohol use disorder in an inpatient treatment protocol at the National Institutes of Health and parsed SSM into 3 groups based on degree of change.</p><p><strong>Results: </strong>The improved SS group had statistically higher initial SSM and a nonstatistically increased liver stiffness measurement compared with others.</p><p><strong>Discussion: </strong>SS is dynamic in a subset of patients immediately after alcohol cessation, and improved SS is associated with a normalization of platelet count.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liraglutide and Colesevelam Changes Serum and Fecal Bile Acid Levels in a Randomized Trial with Patients with Bile Acid Diarrhea. 在一项针对胆汁酸腹泻患者的随机试验中,利拉鲁肽和可乐定会改变血清和粪便中的胆汁酸水平。
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-23 DOI: 10.14309/ctg.0000000000000772
Anne-Marie Ellegaard, Martin L Kårhus, Lukasz Krych, David P Sonne, Julie L Forman, Svend H Hansen, Lars Ove Dragsted, Dennis S Nielsen, Filip K Knop

Introduction: Both liraglutide and colesevelam improve bile acid diarrhea (BAD) symptoms. Colesevelam binds excess amounts of diarrhea-causing bile acids in the colon whereas the mode of action for liraglutide remains elusive. Here, we examined the impact of colesevelam and liraglutide treatment on the concentrations of bile acids in serum and feces and the fecal microbiota composition to better understand the two drugs' modes of action.

Methods: Bile acid species were analyzed in serum and fecal samples from a randomized, double-blind, double-dummy trial at baseline and after three and six weeks of orally administered colesevelam (1,875 mg twice daily, n = 26) or subcutaneously administered liraglutide (uptitrated by weekly increments of 0.6 mg from 0.6 to 1.8 mg daily, n = 26) in patients with 75selenium-homotaurocholic acid test-verified, idiopathic, or post-cholecystectomy BAD. Fecal microbiota composition was analyzed by 16S rRNA gene amplicon sequencing at the same time points.

Results: Colesevelam increased the fecal concentrations of all bile acid species while it decreased serum concentrations of secondary bile acids. Liraglutide induced a small increase in serum unconjugated bile acid concentrations without affecting fecal bile acid concentrations. No changes in fecal microbiota composition were observed with either treatment.

Conclusion: Colesevelam and liraglutide exhibit distinct effects on serum and fecal bile acid concentrations with colesevelam reducing serum concentrations of secondary bile acids and promoting fecal bile acid excretion while liraglutide enhances serum concentrations of unconjugated bile acids, potentially through deceleration of small intestinal transit time allowing more time for passive absorption of bile acids.

简介:利拉鲁肽和可乐塞维兰都能改善胆汁酸腹泻(BAD)症状。可乐塞维兰能结合结肠中过量的导致腹泻的胆汁酸,而利拉鲁肽的作用模式仍不明确。在此,我们研究了可乐塞维兰和利拉鲁肽治疗对血清和粪便中胆汁酸浓度以及粪便微生物群组成的影响,以更好地了解这两种药物的作用模式:方法:在一项随机、双盲、双哑试验中,在口服可乐塞韦兰(1,875 毫克,每天两次,n = 26)或皮下注射利拉鲁肽(从 0.6 毫克到 1.6 毫克,每周递增 0.6 毫克)三周和六周后,对血清和粪便样本中的胆汁酸种类进行分析。6毫克,从每天0.6毫克到1.8毫克,n = 26)。在同一时间点,通过 16S rRNA 基因扩增片测序分析了粪便微生物群的组成:结果:可乐西维兰增加了粪便中所有胆汁酸种类的浓度,同时降低了血清中次级胆汁酸的浓度。利拉鲁肽诱导血清非结合胆汁酸浓度小幅升高,但不影响粪便胆汁酸浓度。两种治疗方法均未观察到粪便微生物群组成的变化:结论:可乐塞韦兰和利拉鲁肽对血清和粪便中胆汁酸的浓度有不同的影响,可乐塞韦兰可降低血清中次级胆汁酸的浓度,促进粪便中胆汁酸的排泄,而利拉鲁肽可提高血清中未结合胆汁酸的浓度,这可能是通过减慢小肠转运时间,使胆汁酸有更多的时间被动吸收。
{"title":"Liraglutide and Colesevelam Changes Serum and Fecal Bile Acid Levels in a Randomized Trial with Patients with Bile Acid Diarrhea.","authors":"Anne-Marie Ellegaard, Martin L Kårhus, Lukasz Krych, David P Sonne, Julie L Forman, Svend H Hansen, Lars Ove Dragsted, Dennis S Nielsen, Filip K Knop","doi":"10.14309/ctg.0000000000000772","DOIUrl":"https://doi.org/10.14309/ctg.0000000000000772","url":null,"abstract":"<p><strong>Introduction: </strong>Both liraglutide and colesevelam improve bile acid diarrhea (BAD) symptoms. Colesevelam binds excess amounts of diarrhea-causing bile acids in the colon whereas the mode of action for liraglutide remains elusive. Here, we examined the impact of colesevelam and liraglutide treatment on the concentrations of bile acids in serum and feces and the fecal microbiota composition to better understand the two drugs' modes of action.</p><p><strong>Methods: </strong>Bile acid species were analyzed in serum and fecal samples from a randomized, double-blind, double-dummy trial at baseline and after three and six weeks of orally administered colesevelam (1,875 mg twice daily, n = 26) or subcutaneously administered liraglutide (uptitrated by weekly increments of 0.6 mg from 0.6 to 1.8 mg daily, n = 26) in patients with 75selenium-homotaurocholic acid test-verified, idiopathic, or post-cholecystectomy BAD. Fecal microbiota composition was analyzed by 16S rRNA gene amplicon sequencing at the same time points.</p><p><strong>Results: </strong>Colesevelam increased the fecal concentrations of all bile acid species while it decreased serum concentrations of secondary bile acids. Liraglutide induced a small increase in serum unconjugated bile acid concentrations without affecting fecal bile acid concentrations. No changes in fecal microbiota composition were observed with either treatment.</p><p><strong>Conclusion: </strong>Colesevelam and liraglutide exhibit distinct effects on serum and fecal bile acid concentrations with colesevelam reducing serum concentrations of secondary bile acids and promoting fecal bile acid excretion while liraglutide enhances serum concentrations of unconjugated bile acids, potentially through deceleration of small intestinal transit time allowing more time for passive absorption of bile acids.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Different etiological entities of liver cancer across populations: Implications from age-period-cohort analysis on incidence trends. 不同人群肝癌的不同病因:年龄-时期-队列分析对发病趋势的影响。
IF 3.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-18 DOI: 10.14309/ctg.0000000000000769
Tian-Wen Chen,Yi-Jun Cheng,Yong-Ying Huang,Zhiqiang Liu,Jing-Feng Liu,Shao-Hua Xie
BACKGROUNDThe incidence of liver cancer has shown different temporal trends across populations, while the underlying reasons remain unclear.METHODSWe examined temporal trends in the incidence of liver cancer in Hong Kong, Sweden, and the United States since the 1970s through 2021 using joinpoint regression and age-period-cohort analysis.RESULTSThe age-standardized incidence rate of liver cancer in Hong Kong steadily decreased (average annual percentage change [AAPC] -2.2%, 95% confidence interval [CI] -2.8% to -1.7% in men; AAPC -2.1%, 95%CI -3.1% to -1.1% in women) in 1983-2020. The rate in Sweden increased on average by 0.8% (95%CI 0.2% to 1.4%) per year in men and was stable in women (AAPC 0.2%, 95%CI -0.9% to 1.4%) in 1970-2021. The rate in the United States increased by 2.1% (95%CI 1.5% to 2.8%) per year in men and by 2.1% (95%CI 1.6% to 2.5%) in women in 1975-2020, but decreasing trends were noted in 2015-2020 (AAPC -6.6%, 95%CI -8.3% to -4.9% in men; AAPC -4.2%, 95%CI -7.5% to -0.5% in women). Stratified analysis by histological type showed such decrease in recent years was limited to hepatocellular carcinoma, rather than intrahepatic cholangiocarcinoma. We observed distinct changes in trends across age groups and different trends across birth cohorts.CONCLUSIONThe incidence of liver cancer has decreased in Hong Kong but increased in Sweden and the United States since the 1980s, despite decreasing incidence in the United States since 2015. Such disparities may be explained by different etiology and implementation of preventive measures across populations.
背景肝癌的发病率在不同人群中呈现出不同的时间趋势,但其根本原因仍不清楚。方法我们使用连接点回归和年龄-时期-队列分析法研究了香港、瑞典和美国自 20 世纪 70 年代至 2021 年肝癌发病率的时间趋势。结果1983-2020年间,香港的肝癌年龄标准化发病率稳步下降(男性平均年百分比变化[AAPC] -2.2%,95%置信区间[CI] -2.8%至-1.7%;女性平均年百分比变化[AAPC] -2.1%,95%置信区间[CI] -3.1%至-1.1%)。1970-2021 年间,瑞典的男性发病率平均每年上升 0.8%(95%CI 为 0.2% 至 1.4%),女性发病率则保持稳定(AAPC 为 0.2%,95%CI 为 -0.9% 至 1.4%)。在美国,1975-2020年男性的发病率每年增加2.1%(95%CI为1.5%至2.8%),女性的发病率每年增加2.1%(95%CI为1.6%至2.5%),但2015-2020年呈下降趋势(男性AAPC为-6.6%,95%CI为-8.3%至-4.9%;女性AAPC为-4.2%,95%CI为-7.5%至-0.5%)。按组织学类型进行的分层分析表明,近年来这种下降仅限于肝细胞癌,而非肝内胆管癌。我们观察到不同年龄组的趋势有明显变化,不同出生组群的趋势也不同。结论自20世纪80年代以来,肝癌发病率在香港有所下降,但在瑞典和美国却有所上升,尽管美国的发病率自2015年以来有所下降。造成这种差异的原因可能是不同人群的病因和预防措施的实施情况不同。
{"title":"Different etiological entities of liver cancer across populations: Implications from age-period-cohort analysis on incidence trends.","authors":"Tian-Wen Chen,Yi-Jun Cheng,Yong-Ying Huang,Zhiqiang Liu,Jing-Feng Liu,Shao-Hua Xie","doi":"10.14309/ctg.0000000000000769","DOIUrl":"https://doi.org/10.14309/ctg.0000000000000769","url":null,"abstract":"BACKGROUNDThe incidence of liver cancer has shown different temporal trends across populations, while the underlying reasons remain unclear.METHODSWe examined temporal trends in the incidence of liver cancer in Hong Kong, Sweden, and the United States since the 1970s through 2021 using joinpoint regression and age-period-cohort analysis.RESULTSThe age-standardized incidence rate of liver cancer in Hong Kong steadily decreased (average annual percentage change [AAPC] -2.2%, 95% confidence interval [CI] -2.8% to -1.7% in men; AAPC -2.1%, 95%CI -3.1% to -1.1% in women) in 1983-2020. The rate in Sweden increased on average by 0.8% (95%CI 0.2% to 1.4%) per year in men and was stable in women (AAPC 0.2%, 95%CI -0.9% to 1.4%) in 1970-2021. The rate in the United States increased by 2.1% (95%CI 1.5% to 2.8%) per year in men and by 2.1% (95%CI 1.6% to 2.5%) in women in 1975-2020, but decreasing trends were noted in 2015-2020 (AAPC -6.6%, 95%CI -8.3% to -4.9% in men; AAPC -4.2%, 95%CI -7.5% to -0.5% in women). Stratified analysis by histological type showed such decrease in recent years was limited to hepatocellular carcinoma, rather than intrahepatic cholangiocarcinoma. We observed distinct changes in trends across age groups and different trends across birth cohorts.CONCLUSIONThe incidence of liver cancer has decreased in Hong Kong but increased in Sweden and the United States since the 1980s, despite decreasing incidence in the United States since 2015. Such disparities may be explained by different etiology and implementation of preventive measures across populations.","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":"6 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142263898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multiple gastrointestinal immune related adverse events from immune checkpoint inhibitor therapy. 免疫检查点抑制剂治疗引起的多种胃肠道免疫相关不良事件。
IF 3.6 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-12 DOI: 10.14309/ctg.0000000000000768
Trevor S Barlowe,Shruti Saxena-Beem,Rumey C Ishizawar,Hans Herfarth,Andrew M Moon
OBJECTIVESDescribe immune related adverse events (irAE) affecting multiple organs of the gastrointestinal system in patients who received immune checkpoint inhibitors (ICI).METHODSWithin a 2843-patient retrospective cohort consisting of patients with cancer treated with ICIs, EMERSE (Electronic Medical Record Search Engine), an information retrieval system, was used to search free text in the medical record to identify patients with multiple gastrointestinal irAEs.RESULTS13 patients developed multiple gastrointestinal irAEs (0.46%). The most common patterns of multisystem gastrointestinal irAE were colitis + pancreatitis and colitis + enteritis.CONCLUSIONSMultisystem gastrointestinal irAEs are rare but warrant further characterization and attention.
目的描述接受免疫检查点抑制剂(ICI)治疗的患者发生的影响胃肠道系统多个器官的免疫相关不良事件(irAE)。方法在由接受 ICIs 治疗的癌症患者组成的 2843 例患者回顾性队列中,使用信息检索系统 EMERSE(电子病历搜索引擎)搜索病历中的自由文本,以识别出现多种胃肠道 irAEs 的患者。结果13 例患者出现多种胃肠道 irAEs(0.46%)。结肠炎+胰腺炎和结肠炎+肠炎是最常见的多系统胃肠道虹吸效应模式。
{"title":"Multiple gastrointestinal immune related adverse events from immune checkpoint inhibitor therapy.","authors":"Trevor S Barlowe,Shruti Saxena-Beem,Rumey C Ishizawar,Hans Herfarth,Andrew M Moon","doi":"10.14309/ctg.0000000000000768","DOIUrl":"https://doi.org/10.14309/ctg.0000000000000768","url":null,"abstract":"OBJECTIVESDescribe immune related adverse events (irAE) affecting multiple organs of the gastrointestinal system in patients who received immune checkpoint inhibitors (ICI).METHODSWithin a 2843-patient retrospective cohort consisting of patients with cancer treated with ICIs, EMERSE (Electronic Medical Record Search Engine), an information retrieval system, was used to search free text in the medical record to identify patients with multiple gastrointestinal irAEs.RESULTS13 patients developed multiple gastrointestinal irAEs (0.46%). The most common patterns of multisystem gastrointestinal irAE were colitis + pancreatitis and colitis + enteritis.CONCLUSIONSMultisystem gastrointestinal irAEs are rare but warrant further characterization and attention.","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":"39 1","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142204852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum Anion Gap at Admission Predicts All-Cause Mortality in Critically Ill Patients With Cirrhosis: A Retrospective Cohort Study. 入院时的血清阴离子差距可预测肝硬化重症患者的全因死亡率:一项回顾性队列研究。
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 DOI: 10.14309/ctg.0000000000000734
Yanqi Kou, Shenshen Du, Mingcheng Zhang, Biao Nie, Weinan Yuan, Kun He, Ling Qin, Shicai Ye, Yuping Yang

Introduction: The primary objective of this study was to evaluate admission serum anion gap (AG) as a predictor of all-cause mortality in critically ill patients with cirrhosis.

Methods: A total of 3,084 cirrhotic patients were included and randomly divided into training and validation cohorts (n = 2,159 and 925, respectively). Patients were categorized into high and normal AG groups based on their AG values. Cox regression and Kaplan-Meier survival analysis were used to assess the relationships between AG levels and outcomes.

Results: Both cohorts showed strong parameter similarity ( P > 0.05). High AG was associated with significantly lower survival probabilities. Cox models confirmed elevated AG as a risk factor, even after adjusting for covariates (hazard ratio: 1.920, 1.793, and 1.764 for 30-day, 60-day, and hospital mortality, respectively). Subgroup analyses, especially regarding chronic kidney disease, revealed complex interactions. Serum AG displayed predictive power comparable with established scoring systems.

Discussion: Elevated AG at admission is a valuable predictor of poor outcomes and increased mortality risk in critically ill cirrhotic patients. Serum AG can serve as an easily accessible tool for risk assessment and prognosis evaluation in this population.

背景和目的:本研究的主要目的是评估肝硬化重症患者入院时血清阴离子差距(AG)作为全因死亡率的预测指标:本研究的主要目的是评估入院血清阴离子间隙(AG)作为肝硬化重症患者全因死亡率预测指标的作用:共纳入 3,084 名肝硬化患者,并随机分为训练组和验证组(分别为 2,159 人和 925 人)。根据 AG 值将患者分为高 AG 组和正常 AG 组。采用 Cox 回归和 Kaplan-Meier 生存分析评估 AG 水平与预后之间的关系:结果:两组患者的参数具有很强的相似性(P > 0.05)。高AG与明显较低的生存概率相关。Cox 模型证实 AG 升高是一个风险因素,即使在调整协变量后也是如此(30 天、60 天和住院死亡率的 HR 分别为 1.920、1.793 和 1.764)。亚组分析,尤其是有关慢性肾病的亚组分析,显示了复杂的相互作用。血清AG的预测能力与已建立的评分系统相当:结论:入院时 AG 升高是预测肝硬化重症患者不良预后和增加死亡风险的重要指标。血清AG可作为该人群风险评估和预后评价的便捷工具。
{"title":"Serum Anion Gap at Admission Predicts All-Cause Mortality in Critically Ill Patients With Cirrhosis: A Retrospective Cohort Study.","authors":"Yanqi Kou, Shenshen Du, Mingcheng Zhang, Biao Nie, Weinan Yuan, Kun He, Ling Qin, Shicai Ye, Yuping Yang","doi":"10.14309/ctg.0000000000000734","DOIUrl":"10.14309/ctg.0000000000000734","url":null,"abstract":"<p><strong>Introduction: </strong>The primary objective of this study was to evaluate admission serum anion gap (AG) as a predictor of all-cause mortality in critically ill patients with cirrhosis.</p><p><strong>Methods: </strong>A total of 3,084 cirrhotic patients were included and randomly divided into training and validation cohorts (n = 2,159 and 925, respectively). Patients were categorized into high and normal AG groups based on their AG values. Cox regression and Kaplan-Meier survival analysis were used to assess the relationships between AG levels and outcomes.</p><p><strong>Results: </strong>Both cohorts showed strong parameter similarity ( P > 0.05). High AG was associated with significantly lower survival probabilities. Cox models confirmed elevated AG as a risk factor, even after adjusting for covariates (hazard ratio: 1.920, 1.793, and 1.764 for 30-day, 60-day, and hospital mortality, respectively). Subgroup analyses, especially regarding chronic kidney disease, revealed complex interactions. Serum AG displayed predictive power comparable with established scoring systems.</p><p><strong>Discussion: </strong>Elevated AG at admission is a valuable predictor of poor outcomes and increased mortality risk in critically ill cirrhotic patients. Serum AG can serve as an easily accessible tool for risk assessment and prognosis evaluation in this population.</p>","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e1"},"PeriodicalIF":3.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141449860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological Analysis on the Impact of Early COVID-19 Pandemic on Mortality for Hepatocellular Carcinoma in the United States. 早期 COVID-19 大流行对美国肝细胞癌死亡率影响的流行病学分析。
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-01 DOI: 10.14309/ctg.0000000000000724
Camilla Mattiuzzi, Giuseppe Lippi
{"title":"Epidemiological Analysis on the Impact of Early COVID-19 Pandemic on Mortality for Hepatocellular Carcinoma in the United States.","authors":"Camilla Mattiuzzi, Giuseppe Lippi","doi":"10.14309/ctg.0000000000000724","DOIUrl":"10.14309/ctg.0000000000000724","url":null,"abstract":"","PeriodicalId":10278,"journal":{"name":"Clinical and Translational Gastroenterology","volume":" ","pages":"e1"},"PeriodicalIF":3.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Translational Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1